2024-07-04 03:39:00 ET
Summary
- Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics.
- The company has above-average margins compared to the broader market, indicating outperformance potential.
- Despite volatility, Merck KGaA presents an interesting upside for investors.
Dear readers/followers,
Sometimes you get really lucky with "timing" your valuation articles. This was the case for my article on Merck KGaA ( MKGAF ), a company I wrote about back in November of 2023. This coverage can be found in an article here, and while the performance during that time compared to the valuation we see now cannot be viewed as "market-beating", the company still has an interesting upside - and I managed to "time" that article very well....
Read the full article on Seeking Alpha
For further details see:
Merck KGaA: The Drop Makes The Upside All The Sweeter